Published in Dis Markers on January 18, 2015
Clinical Significance of SASH1 Expression in Glioma. Dis Markers (2015) 0.78
Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines. Int J Mol Med (2015) 0.78
DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma. Mediators Inflamm (2016) 0.75
The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis. Oncotarget (2016) 0.75
Prominin-1 Is a Novel Regulator of Autophagy in the Human Retinal Pigment Epithelium. Invest Ophthalmol Vis Sci (2017) 0.75
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma. PLoS One (2016) 0.75
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Primary bioassay of human tumor stem cells. Science (1977) 9.69
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood (1997) 7.84
The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg (2009) 2.44
Notch signaling in cancer. Cancer Biol Ther (2002) 2.20
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene (2003) 2.16
Notch signaling promotes airway mucous metaplasia and inhibits alveolar development. Development (2009) 2.10
Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 2.08
Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg (2007) 1.99
The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med (2004) 1.86
Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med (2006) 1.79
The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol (2009) 1.62
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer (2010) 1.56
Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer (2013) 1.41
Gamma-secretase activation of notch signaling regulates the balance of proximal and distal fates in progenitor cells of the developing lung. J Biol Chem (2008) 1.40
Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta (2012) 1.40
Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic (2005) 1.39
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood (2004) 1.38
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol (2013) 1.15
Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9 upregulation. Stem Cells (2012) 1.13
Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res (2010) 1.12
Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers. Cell Commun Signal (2006) 1.12
VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res (2013) 1.08
Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res (2012) 1.07
In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy. BMC Cancer (2010) 1.07
Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int J Clin Exp Pathol (2013) 1.07
Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2010) 1.01
Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer (2012) 1.01
CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol (2013) 0.96
Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer (2011) 0.96
Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun (2014) 0.93
miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2. FEBS Lett (2012) 0.93
CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep (2010) 0.90
Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci (2010) 0.88
Lung cancer stem cells and implications for future therapeutics. Cell Biochem Biophys (2014) 0.87
Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother (2014) 0.86
Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol (2013) 0.84
Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: a case report. Tumori (2013) 0.82
The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol Med Rep (2013) 0.81
Evidence for new standard of care in non-small cell lung cancer patients. Semin Thorac Cardiovasc Surg (2010) 0.80
CD24+/CD38- as new prognostic marker for non-small cell lung cancer. Multidiscip Respir Med (2013) 0.79
Integrated Chinese-western therapy versus western therapy alone on survival rate in patients with non-small-cell lung cancer at middle-late stage. J Tradit Chin Med (2013) 0.76